Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352529 | 0.88 | LTA4H (0.52) | MAPTALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL4352532 | 0.88 | LTA4H (0.52) | MAPTALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL8080901 | 0.82 | MAPT (0.53) | CTDSP1L3MBTL1MAPTALDH1A1HTT | |
| SCHEMBL25299662 | 0.79 | TSHR (0.57) | L3MBTL1MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL24352743 | 0.79 | FKBP1A (0.57) | L3MBTL1MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL6298938 | 0.77 | CYP1A2 (0.59) | L3MBTL1MAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3045885 | 0.75 | MAPT (0.68) | MAPTALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL10643494 | 0.75 | GAA (0.58) | L3MBTL1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2085614 | 0.75 | MAPT (0.62) | MAPTALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL10511967 | 0.74 | ALDH1A1 (0.48) | MAPTALDH1A1HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933390-B2 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | WARNER-LAMBERT COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | BARTH HUBERT (DE) | 2004-12-09 | — | — | US | disclosed |
| US-6774242-B1 | REACTING WITH INDOLE IN APROTIC SOLVENT | GOEDECKE GMBH (DE) | 2004-08-10 | — | — | US | disclosed |
| EP-1165512-A2 | METHOD FOR ARYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS IN THE PRESENCE OF CESIUM CARBONATE | GÖDECKE GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059883-A2 | METHOD FOR PRODUCING N-ARYL-AZA-HETEROCYCLES IN THE PRESENCE OF CESIUM CARBONATE | Gödecke GmbH (DE) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | AZI2, KCNH1, CA7 | CTDSP1 1093/4885L3MBTL1 4876/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.